Abstract
Endothelial dysfunction involving dysfunctional mitochondria precedes the development of cardiovascular diseases. This impairment results from an increase in reactive oxygen species, which leads to oxidative stress and a reduced bioavailability of nitric oxide. It has been demonstrated that oxidative stress and alterations in glucose and lipid homeostasis (e.g. hyperinsulinemia, hyperglycemia, insulin resistance and dyslipidemia) are linked to mitochondrial impairment and that all of them contribute to endothelial dysfunction. Anti-hyperlipidemic drugs such as statins, anti-hypertensive drugs and angiotensin receptor antagonists have been shown to exert protection through anti-oxidative stress mechanisms. Other substances with antioxidant properties, such as vitamins, are also capable of abolishing the oxidative stress associated with cardiometabolic diseases. However, the results obtained with general antioxidants in clinical trials are contradictory, perhaps due to the unspecific nature of the targets selected. This study correlates endothelial dysfunction and mitochondrial dysfunction and examines current research for the selective targeting of specific molecules (such as ·NO donors and antioxidants) to mitochondria with the aim of protecting the endothelium against oxidative stress in cardiovascular diseases.
Keywords: Cardiovascular diseases, endothelial dysfunction, mitochondria, mitochondria-targeted antioxidants, oxidative stress.
Current Medicinal Chemistry
Title:Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Volume: 21 Issue: 25
Author(s): Nadezda Apostolova, Milagros Rocha, Susana Rovira-Llopis, Celia Banuls, Rosa Falcon, Raquel Castello, Antonio Hernandez-Mijares and Victor M. Victor
Affiliation:
Keywords: Cardiovascular diseases, endothelial dysfunction, mitochondria, mitochondria-targeted antioxidants, oxidative stress.
Abstract: Endothelial dysfunction involving dysfunctional mitochondria precedes the development of cardiovascular diseases. This impairment results from an increase in reactive oxygen species, which leads to oxidative stress and a reduced bioavailability of nitric oxide. It has been demonstrated that oxidative stress and alterations in glucose and lipid homeostasis (e.g. hyperinsulinemia, hyperglycemia, insulin resistance and dyslipidemia) are linked to mitochondrial impairment and that all of them contribute to endothelial dysfunction. Anti-hyperlipidemic drugs such as statins, anti-hypertensive drugs and angiotensin receptor antagonists have been shown to exert protection through anti-oxidative stress mechanisms. Other substances with antioxidant properties, such as vitamins, are also capable of abolishing the oxidative stress associated with cardiometabolic diseases. However, the results obtained with general antioxidants in clinical trials are contradictory, perhaps due to the unspecific nature of the targets selected. This study correlates endothelial dysfunction and mitochondrial dysfunction and examines current research for the selective targeting of specific molecules (such as ·NO donors and antioxidants) to mitochondria with the aim of protecting the endothelium against oxidative stress in cardiovascular diseases.
Export Options
About this article
Cite this article as:
Apostolova Nadezda, Rocha Milagros, Rovira-Llopis Susana, Banuls Celia, Falcon Rosa, Castello Raquel, Hernandez-Mijares Antonio and Victor M. Victor, Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases, Current Medicinal Chemistry 2014; 21 (25) . https://dx.doi.org/10.2174/0929867321666140601200416
| DOI https://dx.doi.org/10.2174/0929867321666140601200416 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Current concepts in the study of new therapeutic targets and the development of drugs for diseases of the central nervous system
Central nervous system (CNS) diseases are among the leading causes of chronic disability and mortality worldwide. According to the World Health Organization (WHO), neurological disorders affect over 1 billion people, and the cost of their treatment increases annually. However, advances in neuroscience and medicine are enabling fundamentally new approaches to ...read more
Sustainable Molecular Design for Health and Economy: New Directions in Medicinal Chemistry
The evolving landscape of medicinal chemistry is increasingly influenced by the urgent need to reconcile human health priorities with sustainability imperatives and economic feasibility. While drug discovery and therapeutic development pipelines lead to substantive scientific outcomes, they nonetheless remain disproportionately resource-intensive, environmentally taxing, and financially enclosed. In response to these ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Does Global Gene Expression Analysis in Type 2 Diabetes Provide an Opportunity to Identify Highly Promising Drug Targets?
Endocrine, Metabolic & Immune Disorders - Drug Targets EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Electrocardiographic Patterns and Ejection Fraction in Patients with Nonischemic Dilated Cardiomyopathy: A Cross-sectional Retrospective Study
New Emirates Medical Journal The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Tetramethylpyrazine Facilitates Functional Recovery after Spinal Cord Injury by Inhibiting MMP2, MMP9, and Vascular Endothelial Cell Apoptosis
Current Neurovascular Research Successfully Resuscitated Sudden Cardiac Death in a Young Homosexual Male with HIV Myocarditis
Current HIV Research Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Pathophysiological Mechanisms Underlying Excess Risk for Diabetes and Cardiovascular Disease in South Asians: The Perfect Storm
Current Diabetes Reviews





